H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics to $100 from $75 and keeps a Buy rating on the shares. The company’s research and development day demonstrated sonelokimab data strength, “with an intriguing vision of the future,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MLTX:
- MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
- 3 Best Stocks to Buy Now, 3/5/2024, According to Top Analysts
- MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
- MoonLake Immunotherapeutics price target raised to $80 from $77 at Guggenheim
- MoonLake Immunotherapeutics reports Q4 EPS (12c), consensus (23c)
